Back to results
US 2025/0367289 A1Published application
Dosage regimen for a combination therapy consisting oftcr-engineered t-cells in combination with a pd-1 axis binding antagonist
AssigneeAdaptimmune Limited
InventorsJose SARO, Steve DAWE, Alejandro GARCIA
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a method of treating cancer, and to a population of modified T cells for use in a method of treating cancer.
Claims25
A method of treating cancer in an individual, comprising:
- (a) administering to the individual a population of modified T cells comprising a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4;
- and
- (b) sustaining the function of (i) the population of modified T cells and/or (ii) endogenous T cells in the individual by administering an initial dose of a PD-1 axis binding antagonist to the individual about three weeks to about five weeks after step (a).
A population of modified T cells for use in a method of treating cancer in an individual, wherein the modified T cells comprise a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4, and the method comprises:
- (a) administering the population to the individual;
- and
- (b) sustaining the function of (i) the population of modified T cells and/or (ii) endogenous T cells in the individual by administering an initial dose of a PD-1 axis binding antagonist to the individual about three weeks to about five weeks after step (a).
A PD-1 axis binding antagonist for use in a method of treating cancer in an individual, wherein the method comprises:
- (a) administering to the individual a population of modified T cells comprising a heterologous CD8 co-receptor and a heterologous TCR capable of binding to MAGE-A4;
- and
- (b) sustaining the function of (i) the population of modified T cells and/or (ii) endogenous T cells in the individual by administering an initial dose of the PD-1 axis binding antagonist to the individual about three weeks to about five weeks after step (a).
Dependencies are inferred from the claim text.